Solaris Endovascular today announced its formation to develop solutions for dialysis access and treating peripheral artery ...

The prospective, multicenter ROADSTER 3 postapproval trial is evaluating the safety and effectiveness of transcarotid artery re ...

Abbott, Medtronic, Boston Scientific Corporation ... the market is segmented based on product type (drug-eluting stent (DES), ...

Before 2012, nearly half of Boston Scientific’s business grew by less than 4 percent a year. Now, nearly half of the company ...

Abbott, Boston Scientific, Medtronic, Biotronik, Terumo Corporation, and B. Braun SE are the leading global coronary stents market companies. These vendors are continuously developing and ...

The major global peripheral vascular devices industry players include Abbott Laboratories, Boston Scientific ... These include stents, catheters and angioplasty balloons; which are used to ...

We recently compiled a list of the 10 Best Low Volatility Stocks to Invest in Now. In this article, we are going to take a ...

This acquisition is expected to help the company’s progress in vascular medicine ... single-use imaging and metal stents franchises. Within Urology, Boston Scientific continues to expand ...

The global non-vascular stents market is on the verge of significant expansion, expected to achieve a compound annual growth rate (CAGR) of 4.5% from 2022 to 2032. Valued at USD 1.21 billion in 2022, ...

Investors with a lot of money to spend have taken a bearish stance on Boston Scientific (NYSE:BSX). And retail traders should know. We noticed this today when the trades showed up on publicly ...

Results from the large-scale randomized ECLIPSE trial found that a lesion preparation strategy of routine orbital atherectomy had similar outcomes compared with conventional balloon angioplasty prior ...

Boston Scientific reported Q3 revenue of $4.21 billion, beating estimates. EPS reached $0.63, surpassing consensus of $0.59. Cardiovascular sales rose 25%, and MedSurg increased 10.3% ...